CliffBio
small molecule

TOSYMRA

SUMATRIPTAN

Loss of exclusivityJuly 2031latest FDA-listed patent expiry
CompanyTONIX MEDICINES INC

Drug detail

Brand nameTOSYMRA
Active ingredientSUMATRIPTAN
Strength10MG/SPRAY
Dosage formSPRAY
RouteNASAL
ModalitySmall molecule
FDA approvalJanuary 2019
Marketing statusRX

Listed patents

PatentExpiresType
9211282July 2031product
9974770June 2030product
11337962June 2030product
10603305June 2030product
9610280June 2030product
12090139June 2030product
9283280May 2026product
8440631May 2026product
8268791May 2026product

More from TONIX MEDICINES INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TOSYMRA patent cliff — loss of exclusivity July 2031 | CliffBio